Molecular Interventions 7:261-270, (2007)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.7.5.8
Reviews
BEYOND AMYLOID: The Next Generation of Alzheimer’s Disease Therapeutics
Guy R Seabrook1,
William J. Ray1,
Mark Shearman2 and
Michael Hutton2
1 Dept Alzheimer’s Research, Merck Research Laboratories, West Point, PA 19486
2 Neuroscience Drug Discovery, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115
 |
SUMMARY
|
|---|
The precise pathological events that cause cognitive deficits in Alzheimer’s disease remain to be determined. The most widely held view is that accumulation of amyloid ß peptide initiates the disease process; however, with more than eighteen amyloid-based therapeutic candidates currently in clinical trials, the targeting of amyloid alone may not be sufficient to improve functional deficits over the course of the disease. Alternative targets, such as the tau protein and apolipoprotein E, have thus been increasingly investigated, and in the future, therapeutic strategies will likely address events that are upstream of a more broadly construed pathological cascade that includes but is not limited to the generation and accumulation of amyloid ß. Consideration of such events provides the basis for an "indirect amyloid hypothesis," for which data are beginning to emerge. Although it is clinically defined by simple post-mortem criteria, Alzheimer’s disease likely has a complex etiology, and effective treatments for this disease will become ever more urgent as the world’s population ages.
|
INTRODUCTION
|
|---|
The most widely accepted view of the pathogenic events that culminate in Alzheimer’s disease (AD) centers around the proteolytic generation of the amyloid ß peptide (Aß) and its accumulation in the brain [for review, see (1, 2)]. The Aß cascade hypothesis holds that the accumulation of aggregated Aß species is the key initiating event in the development of AD, although the precise species of Aß that drives neurotoxicity is one of the many uncertainties that remain to be resolved. This hypothesis continues to be controversial (3) and has yet to be formally tested; however, it is supported by compelling genetic evidence. Mutations in either the gene that encodes the amyloid precursor protein (APP) or in genes that encode components involved in the processing of APP [e.g., presenilin-(PSEN)-1] can lead to familial AD. Indeed, such mutations either increase the generation of Aß42, the more amyloidogenic form of Aß, or increase the tendency of Aß to aggregate, and along with triplication of the region of chromosome 21 that encodes APP, they account for all known cases of inherited AD (4). Moreover, variation in the gene that encodes apolipoprotein E (APOE) has been linked to AD, and there is good evidence that APOE genotype influences amyloid deposition either directly or by affecting the rate of Aß clearance from the brain (5, 6). Finally, several other forms of amyloidosis are associated with progressive neurodegeneration, such as British Dementia, in which case the analogous precursor protein carries a C-terminal extension that aggregates and deposits into amyloid plaques associated with disease progression (7). The obvious parallel between the pathogenesis of British Dementia, which depends on the generation of a mutant amyloidogenic peptide, and AD provides further support for the Aß cascade hypothesis.
In addition to genetic data, a multitude of studies have shown that Aß can be toxic to neurons in culture, and several studies have recently shown that specific oligomeric Aß species, when injected into rodents, cause memory deficits (8–10). Indeed, increasing evidence indicates that overexpression or accumulation of various Aß species consistently results in synaptic dysfunction in mice expressing mutant APP alone or in combination with presenilin transgenes (11–16). Consequently, many pharmaceutical companies have invested in the discovery of small-molecule and biologic agents that target specific components of the amyloid cascade (17, 18). Over seventy-five compounds are in clinical development for the treatment of AD, of which greater than 80% are based on either amyloid-specific mechanisms or on neurotransmitter pathways (Table 1
; Figure 1); the latter are primarily palliative, aimed at affecting learning and memory. Here, we focus on therapeutic discovery that has not been primarily driven by the amyloid hypothesis. We also discuss how modern genome-wide small interfering RNA (siRNA) screens and molecular profiling can be employed to further delineate pathways in AD development, independent of their potential role in Aß generation.
|
BEYOND THE AMYLOID HYPOTHESIS
|
|---|
The central nervous system has proved to be a challenging area for drug discovery, which undoubtedly reflects the complex nature of the brain. Likewise, it should not be a surprise to learn that the majority of clinical development candidates fail not only because of safety or tolerability issues, but also because of flawed hypotheses that may require more than a decade’s worth of investigation prior to testing in patients (19). These considerations, and recent disappointing results from phase III trials of the anti-amyloidogenic agent tramiprosate, underscore the necessity of exploring therapeutic targets for Alzheimer’s disease in a broader context than that offered by the amyloid hypothesis.
Despite the wealth of evidence indicating a central role for Aß in the etiology of AD, there are significant problems with a simplistic hypothesis in which aggregated Aß species directly cause neuronal dysfunction and lead to the clinical phenotype. First, there is the well-documented lack of correlation between the extent of amyloid pathology in the brains of AD patients and clinical progression (20). Indeed, a significant number of asymptomatic individuals show extensive, if diffuse, amyloid deposition at autopsy (21). A further complication is that at least in early-stage AD, neuronal loss and amyloid deposition occur in different brain regions (22). Both issues have yet to be satisfactorily explained within a minimal amyloid cascade model, although biochemical studies have indicated that soluble Aß species may display a more convincing link to disease progression (23). A further problem with a simple interpretation of the amyloid cascade model is that mice expressing mutant APP transgenes either alone or with a PSEN1 mutant transgene develop extensive amyloid disposition but fail to show frank neuronal loss (24). Indeed, even the extent of synaptic loss varies markedly among different APP- and PSEN1-expressing lines (24). As a result, it seems difficult to argue that exposure to disease-relevant levels of Aß species directly causes acute neurodegeneration in vivo. Consistent with the absence of neurodegeneration, mouse models that overexpress APP (with or without PSEN1) fail to develop intracellular neurofibrillary tangles (NFTs), which next to amyloid plaques is a primary pathological feature of AD.
All of these concerns might be addressed by modification of the amyloid cascade hypothesis, such that accumulation of Aß species may initiate the disease process, but a secondary pathogenic event is required for subsequent neurodegeneration. Dysfunction affecting the microtubule-associated protein tau (MAPT), which gives rise to NFTs, is an obvious candidate for this secondary event. NFTs correlate well with clinical progression in AD, and transgenic mice that express mutant MAPT protein and develop widespread NFTs almost inevitably have neuronal loss in affected brain regions (20, 24).
The potential consequence of this modified scheme is that strategies that target Aß in order to prevent or clear amyloid deposits could prevent the onset of disease but would have limited benefit in patients with established clinical symptoms. Indeed, autopsy studies in patients treated with the Elan Pharmaceuticals vaccine that elicited robust antibody titers against Aß peptide indicate effective clearance of amyloid plaque pathology; in contrast, the tau pathology in these patients showed no evidence of reduction (25, 26). Twelve months after immunization, patients displayed little clinical benefit (27). These results are consistent with our modified hypothesis, according to which symptoms of neurodegeneration would reflect a point or event in AD progression where Aß reduction alone may have little effect.
A further complication to the simple, linear amyloid cascade hypothesis comes from indications of molecular mechanisms that indirectly influence amyloid production and likely contribute to the neurodegenerative process in AD. One example comes from a recent study in which hypoxia was reported to cause upregulation of the enzyme that cleaves APP and generates the N terminus of Aß [i.e., the beta-site APP-cleaving enzyme (BACE)] (28). Along similar lines, brain injury resulting from almost any insult will induce Aß deposition, perhaps by increased expression of acute phase proteins, including APP and APOE (29, 30). As a result, even if the amyloid cascade hypothesis is fundamentally correct, the clinical symptoms in AD may result from a complex interplay of Aß-induced neurodegenerative processes along with insults that indirectly influence Aß production and/or deposition. In turn, these variables would complicate treatment with anti-amyloid strategies, particularly in subsets of patients where the Aß-driven component of the disease is relatively minor.
|
PALLIATIVE THERAPEUTIC MODULATION OF NEUROTRANSMITTERS IN AD
|
|---|
The palliative treatment of AD has been practiced for over a decade in the form of AChE inhibitors and glutamate receptor modulators (31). These approaches target the symptomatic deficits in the disease and have significant but modest clinical benefit in specific patient groups. Whether these agents effectively modify disease course continues to be debated at the epidemiological level (32), but there is no compelling evidence that they fundamentally change the underlying disease pathology. Nevertheless, second-generation neurotransmitter strategies may provide a means of testing the indirect amyloid approach. For example, muscarinic agonists not only promote cognition directly, but also inhibit the development of amyloid and tau pathology in a model of AD based on triple transgenic (i.e., APP-, PSEN1-, and tau-expressing) mice (33). Although the underlying mechanism is not clear, the results imply that muscarinic compounds may thus influence the etiology of AD as well as provide symptomatic benefit (34). Several companies are investigating activators of nicotinic acetylcholine receptors and AMPA receptors; however, the potential of these therapeutics to modify the underlying disease pathogenesis is less clear.
|
TAU—THE OTHER "AMYLOID"
|
|---|
The identification of pathogenic mutations in the tau-encoding gene (i.e., MAPT) in patients with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) demonstrates that tau dysfunction can be sufficient to cause neurodegeneration (35, 36). Furthermore, a common MAPT haplotype (H1) is a major risk factor for progressive supranuclear palsy and corticobasal degeneration, two sporadic tauopathies that lack highly penetrant pathogenic MAPT mutations (37, 38). These genetic findings, along with the established correlation between NFT pathology and clinical progression, corroborate the important role that tau plays in the development of AD.
The nature of the MAPT mutations found in FTDP-17 patients suggest that tau-associated neurodegeneration arises either from a conformational change in tau, leading to aggregation, or from tau dysfunction, leading ultimately to microtubule instability (35, 36, 39). Hyperphosphorylation is a common feature of the tau species incorporated into neurofibrilliary lesions in all of the tauopathies, including AD, and hyperphosphorylation has also been shown to block tau binding to microtubules, potentially resulting in a loss of microtubule stability (3). As a result, reported tau-based drug discovery has focused on: i) preventing the accumulation and aggregation of pathological tau species (40, 41); ii) preventing microtubule destabilization that may occur as a result of tau dysfunction (42); and most commonly, iii) inhibiting kinases that have been linked to tau hyperphosphorylation (43–46).
|
LESSONS FROM RISK FACTORS IN LATE-ONSET AD
|
|---|
The clearest genetic risk factor for late-onset AD (LOAD) is the presence of the 
4 allele of the APOE gene (47). Although individuals homozygous for the 4 allele have fifteenfold the risk of AD compared to individuals homozygous for the 3 allele, mechanistically there has been a paucity of data leading directly to traditional druggable targets. However, scientists at the Gladstone Institute have recently identified potential targets for drug intervention based on disruption of protein conformational structure (48). The difficulty in identifying tractable targets based on APOE4 biology is linked to the complexity of its involvement in brain lipid metabolism and by the incomplete penetrance of this genetic risk factor in the disease. A further complexity is that APOE genotype clearly influences Aß deposition, even if only indirectly. Elderly individuals with the 4/4 and 4/3 genotypes display greater amyloid pathology regardless of whether they are diagnosed with AD, another neurodegenerative disease, or are unaffected at time of death (7). The potential complexity of the role of APOE in AD raises a particularly interesting concern: If APOE offers us the best chance for elucidating genetic risk factors for AD, then how realistic is it to expect to unravel the mechanisms of less penetrant risk factors? The question is daunting, and answers will likely require genome-wide expression data to identify pathways for exploration.
|
BIOMARKERS AS CLUES TO AD PATHOLOGY
|
|---|
Fluid biomarker studies of cerebrospinal fluid (CSF) from patients with AD have also identified a number of pathways that may provide clues to therapeutic intervention. In one study, using two-dimensional gel electrophoresis of CSF samples from patients (49), a panel of proteins that distinguish AD from control with an accuracy of 94% was identified. These protein markers are predominantly involved in Aß transport (e.g., APOE), inflammation (e.g., complement proteins), or protease inhibition , and neuronal membrane proteins such as neuronal pentraxin receptor. Other studies have similarly identified members of the complement cascade as well as proteins of the folate-homocysteine cycle (50–52).
Indeed, many prospective studies now confirm that elevated plasma homocysteine substantially increases risk for dementia in the elderly. It is not clear if plasma homocysteine, a common risk factor in many diseases (e.g., atherosclerosis), contributes to AD pathogenesis or simply marks it. Sontag and coworkers (53) have recently shown that disruption of homocysteine metabolism in mice affects both amyloid and tau pathology in rodents. Intriguingly, this disruption decreases methylation of phosphatase 2a, a phenomenon that is also seen in AD tissue. Studies on AD fluid biomarkers, particularly at different stages of the disease and in at-risk populations, will inevitably yield many further clues. The ongoing government–industry sponsored Alzheimer’s Disease Neuroimaging Initiative (ADNI; http://www.loni.ucla.edu/ADNI), inspired by the late Leon Thal, will provide a unique resource to qualify some of these biomarkers and assess their functional relevance to disease pathology and neuropsychiatric endpoints.
|
BEYOND AMYLOID AS DIRECT TARGET
|
|---|
Regardless of whether it is the direct cause of neurodegeneration, Aß deposition is a relatively specific hallmark of AD, and multiple pathogenic mechanisms most likely contribute to its accumulation. Thus, an attractive new area for investigation is to identify processes that lead indirectly to increased amyloid deposition.
CHOLESTEROL HOMEOSTASIS AND LIPID SIGNALING
Cholesterol homeostasis is of interest (54) because of the fundamental role APOE plays as the major cholesterol carrier in the brain. In addition, hypercholesterolemia has been implicated as a risk factor for AD (55), and membrane cholesterol promotes Aß production, whereas Aß40 inhibits cholesterol synthesis (56). Epidemiological studies indicate that cholesterol-lowering medications such as simvastatin may be associated with a reduced risk of dementia in the elderly (55).
Given the tremendous therapeutic success of modulating peripheral cholesterol for cardiovascular disease, one can imagine that there are also additional safe points of intervention into brain lipid metabolism. Among targets that have been proposed are acyl-CoA:cholesterol acyltransferase (ACAT), inhibition of which reduces the pool of brain cholesterol esters and lowers Aß in transgenic mice. The nuclear receptor LXRß, which binds oxysterols and thereby stimulates the transcription of genes involved in cholesterol efflux from the brain (e.g., APOE and ABCA1), is also promising. Specifically, LXRß activation by synthetic ligands increases ABCA1 levels and reduces amyloid load in transgenic mice (57, 58). The low-density lipoprotein receptor–related protein (LRP) appears to promote Aß formation in murine models (59); inhibition of the LRP–APOE interaction might thus positively affect both APOE and amyloid pathways. Additional targets include the cytochrome P450-(CYP)-46 enzyme, exclusively expressed in the brain, which eliminates brain cholesterol by oxidation to 24-hydroxycholesterol, which diffuses out of the brain. In mice, CYP46 is required for cholesterol homeostasis and proper synaptic function (60), and its pharmacological activation could conceivably inhibit amyloid production, although this hypothesis remains to be tested. Future interest could also include the oxysterol binding proteins (OSBPs), an intriguing family of lipid transporters that bind oxysterols and modulate cell signaling and membrane trafficking (61). Although each of these potential targets faces significant hurdles, the field of brain cholesterol homeostasis exemplifies the indirect amyloid approach.
ENERGIZING THE BRAIN IN AD
Another emerging field is brain energy homeostasis. AD patients show profound reductions in brain glucose uptake and metabolic activity early in the disease process (62), and mitochondrial dysfunction has long been suspected in AD pathogenesis (63). Conversely, adults with high education, strong linguistic skills, and a mentally active lifestyle seem to be protected from AD (64, 65). Studies in transgenic mice show that levels of Aß are reduced by voluntary exercise (66) and mental activity (67, 68) , whereas they are raised upon energy deprivation by 2-deoxyglucose (69).
Other data raise the possibility that biochemical pathways regulating brain energy metabolism could be targets in AD. Indeed, rosiglitazone, an agonist of peroxisome proliferator-activated receptor-(PPAR)-
, has recently shown hints of efficacy in a subpopulation of AD patients (70) by a mechanism that is hypothesized to involve modulation of neuronal mitochondrial function (71).
OTHER PATHWAYS INTO AD
There is also abundant evidence linking inflammation, which likely plays a key role in most age-related degenerative diseases, with Aß production and toxicity (72). Peripheral anti-inflammatory strategies have yielded effective medicines for many conditions, and it thus seems plausible that specific pathways that modulate microglial activation and influence Aß accumulation or toxicity could be targeted. Finally, a connection between Aß and cerebral vasculature pathology has long been appreciated, and recent studies identify serum response factor and myocardin as transcription factors, overexpressed in vascular smooth muscle cells in AD patients, that might mediate arterial hypercontractility (73). Preventing the aberrant expression of these and other factors could represent indirect amyloid strategies. These examples are not exhaustive—similar strategies could focus on oxidative stress, elevated autophagy/lysosomal dysfunction, calcium dysregulation, aberrant cell cycle entry, and related pathways.
|
GENOMIC ANALYSIS OF RISK FACTORS
|
|---|
Functional genomics offers the opportunity to identify factors leading to amyloid accumulation or toxicity in an unbiased fashion, so that indirect amyloid targets are not overlooked by design (Figure 3). A genome-wide siRNA screen has validated this unbiased approach to factors that regulate APP processing and secretion (74). Among the genes identified in this way was LRRTM3, which encodes leucine-rich repeat transmembrane protein 3, a novel neuronal receptor-like protein that promotes the proteolytic processing of APP by BACE. Although its function is unknown, LRRTM3 is from the same family as the SLIT receptor kinases and the NOGO receptor, critical regulators of axon guidance, synaptogenesis, and neuroregeneration; the NOGO receptor negatively regulates Aß production in mice (75). Combined with data suggesting a role for APP in synaptic regulation (76–78), along with the emerging concept that AD involves fluctuations in neurological function (79), these genomic data may culminate in a therapeutic strategy aimed at stabilizing synaptic activity. Specifically, one can envision neuronal proteins such as LRRTM3 and the NOGO receptor as targets of early investigation. Likewise, saturation mutagenesis experiments in model organisms will yield new hypotheses drug targets. Paired with appropriately powered human genetics studies and the identification of disease progression biomarkers, research in AD and related areas could experience a profusion of hypotheses, irrespective of the amyloid hypothesis, that will form the bases for future clinical trials.
View larger version (79K):
[in this window]
[in a new window]
|
Figure 3. The convergence of two distinct genomic screens that together identify genes that regulate APP processing and amyloid neurotoxicity. A) The development of inhibitors APP proteolysis (i.e., inhibitors of -secretase) for the treatment of Alzheimer’s disease has been hampered by mechanism-based toxicities. To identify novel regulators/modulators of APP processing, a whole-genome siRNA screen was conducted in HEK293 cells expressing the NEFV mutant of APP—an engineered mutation that facilitates cleavage and assay of the Aß42 fragment. Viability and multiple endpoints of APP processing were monitored, including the production of Aß40, Aß42, soluble APPß (sAPPß), and soluble APP (sAPP). Hits were selected based on high-throughput results within two standard deviations from the mean as well as by patterns of inhibition reflecting BACE-like activity (i.e., decrease in Aß40, Aß42, and sAPPß and an increase in sAPP). [See (74).] B) The expression of human Aß42 peptides in fruit flies results in decreased lifespan, locomotor deficits, and rough-eye phenotype. These characteristics are not observed in flies expressing the benign human Aß40 peptide and are exacerbated in flies expressing either a double dose of Aß42 or aggregation-prone forms of Aß42. A p-element genetic screen was performed to identify genes that, when overexpressed or disrupted, would rescue flies that express an aggregation-prone form of Aß42. Several genes were identified that rescue Aß42-mediated toxicity and are currently under investigation. [See (80).] C) Exploring protein-protein interaction networks reveal a convergence of the data sets indicating that pathways that regulate APP processing may also play a role in mitigating Aß42 related neurodegeneration.
|
|
|
CONCLUSIONS AND FUTURE PERSPECTIVES
|
|---|
Academia, government, and industry have all made huge investments into research to understand the biology and potential therapeutic points for intervention in AD. The aging population and recent failures of large late-stage clinical studies involving amyloid-directed strategies highlight the sense of urgency. However, emerging evidence about pathways that may lie upstream of amyloid generation sustain efforts to intervene into AD progression. Research focused on mechanisms indirectly related to amyloid production will likely provide the basis for the next generation of targets for AD. However, no validated animal models are yet available to test the efficacy of such approaches to the disease, and proof of concept will involve large and extended clinical studies. This situation highlights the need for further research into disease biomarkers. Such biomarkers cannot realistically be expected to become a surrogate for the disease in the near term, but they will become crucial to establishing markers of central target engagement and will perhaps provide clues to alternate targets for therapeutic intervention. Disease biomarkers are also needed to prioritize research investments into those compounds and approaches that are likely to have the highest probability of efficacy against AD. Thus, an integrated approach to treating AD is essential to success in fighting this disease (Figure 4). This integration will necessitate a comprehensive understanding of the genetics of vulnerable patients, an appropriate use of diagnostics and disease state biomarkers, as well as imaging and neuropsychiatric endpoints to track disease progression and therapeutic outcomes.
View larger version (35K):
[in this window]
[in a new window]
|
Figure 4. A picture of the future: the Alzheimer’s disease healthcare cycle. This schematic highlights the importance of taking an integrated approach to identification of novel therapeutic targets for Alzheimer’s disease by considering not just the genetic basis of a given target but also its biological context and how biomarkers coupled to clinical endpoints will be needed to measure efficacy to establish medical value to patients and caregivers.
|
|
| |
Guy R. Seabrook, PhD, studied neurophysiology at the University of Nottingham (UK) and subsequently pursued postdoctoral work in both academia and industry. He joined Merck’s West Point PA facility in 2002 and led the Therapeutic Area Group for basic research into movement disorders. He is currently Head of Department for West Point Alzheimer’s Research and has worked on numerous successful drug discovery projects and development teams. Address correspondence to GRS. E-mail guy_seabrook{at}merck.com; fax 215-652-2075.
|
|
| |
Michael Hutton, PhD, completed his doctoral work at University of Cambridge, UK, and subsequently rose through positions in academia. His laboratory, identified mutations in MAPT that cause frontotemporal dementia, demonstrating that tau dysfunction is sufficient to cause neurodegeneration, and went on to elucidate, through the development and use of elegant transgenic mouse models, the roles of tau and the growth factor progranulin in distinct AD-associated processes. Dr Hutton recently moved to Merck Research Laboratories in Boston to head a group that will focus on AD and related neurodegenerative conditions.
|
|
| |
Mark Shearman, PhD, studied biochemistry at the University of Nottingham (UK) and pursued postdoctoral appointments in Japan and Germany. He has played multiple leadership roles since joining Merck in 1992, and in 2006 moved to the new MRL research facility in Boston to establish and lead neuroscience efforts as Executive Director, Neuroscience Drug Discovery. Dr Shearman’s research has advanced understanding of the -secretase enzyme complex and its role in Alzheimer’s disease pathophysiology.
|
|
View larger version (45K):
[in this window]
[in a new window]
|
Figure 2. The indirect amyloid hypothesis of Alzheimer’s disease. Large arrows represent upstream events that may contribute to network dysfunction and subsequently neurological damage. Smaller black arrows are indicative of downstream contributory factors that are likely to be important once the disease is established.
|
|
|
ACKNOWLEDGMENTS
|
|---|
We would like to thank Lennart Mucke for critical insights on this review. Also, we would like to thank Luiz Miguel Camargo, Uwe Beffert, and Dianne McDonald-Harmer for their contributions in preparation of this manuscript, as well as Richard Page, David Lomas, and Damian Crowther (University of Cambridge, UK) for their collaborative and pioneering work on the Drosophila amyloid model.
|
References
|
|---|
- Kola, I. and Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715 (2004).[CrossRef][Medline]
- Roberson, E.D. and Mucke, L. 100 years and counting: Prospects for defeating Alzheimer’s disease. Science 314, 781–784 (2006).[Abstract/Free Full Text]
- Walsh, D.M. and Selkoe, D.J. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 44, 181–193 (2004).[CrossRef][Medline]
- Lee, V.M., Goedert, M., and Trojanowski, J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci., 24, 1121–1159 (2001).[CrossRef][Medline]
- Hardy, J. Alzheimer’s disease: The amyloid cascade hypothesis: An update and reappraisal. J. Alzheimers Dis. 9, 151–153 (2006).[Medline]
- Holtzman, D.M., Bales, K.R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A.M., Chang, L.K., Sun, Y., and Paul, S.M. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer’s disease. J. Clin. Invest. 103, R15–R21 (1999).[Medline]
- Josephs, K.A., Tsuboi, Y., Cookson, N., Watt, H., and Dickson, D.W. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. Arch. Neurol. 61, 1579–1584 (2004). One of several neuropathological studies that have established that the 4 allele of APOE enhances, regardless of clinical diagnosis, amyloid deposition in patients.[Abstract/Free Full Text]
- Vidal, R., Frangione, B., Rostagno, A., Mead, S., Revesz, T., Plant, G., and Ghiso, J. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 399, 776–781 (1999).[CrossRef][Medline]
- Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., and Selkoe, D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).[CrossRef][Medline]
- Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., and Ashe, K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352–357 (2006).[CrossRef][Medline]
- Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., and Sabatini, B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866–2875 (2007).[Abstract/Free Full Text]
- Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. Correlative memory deficits, A-beta elevation, and amyloid plaques in transgenic mice. Science 274, 99–102 (1996).[Abstract/Free Full Text]
- Holcomb, L., Gordon, M.N., McGowan, E. et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Nat. Med. 4, 97–100 (1998).[CrossRef][Medline]
- Chapman, P.F., White, G.L., Jones, M.W. et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2, 271–276 (1999).[CrossRef][Medline]
- Fitzjohn, S.M., Morton, R.A., Kuenzi, F. et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J. Neurosci. 21, 4691–4698 (2001).[Abstract/Free Full Text]
- Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., and Malinow, R. APP processing and synaptic function. Neuron 37, 925–937 (2003).[CrossRef][Medline]
- Palop, J.J., Chin, J., Roberson, E.D. et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron 55, 697–711 (2007).[CrossRef][Medline]
- Best, J.D., Smith, D.W., Reilly, M.A. et al. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclo hexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J. Pharmacol. Exp. Ther. 320, 552–558 (2007).[Abstract/Free Full Text]
- Lindsley, S.R., Moore, K.P., Rajapakse, H.A. et al. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 17, 4057–4061 (2007).[CrossRef][Medline]
- Braak, H. and Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol.(Berl) 82, 239–259 (1991).[CrossRef][Medline]
- Braak, E., Griffing, K., Arai, K., Bohl, J., Bratzke, H., and Braak, H. Neuropathology of Alzheimer’s disease: What is new since A. Alzheimer? Eur. Arch. Psychiatry Clin. Neurosci. 249 Suppl 3, 14–22 (1999).
- Carter, J. and Lippa, C.F. Beta-amyloid, neuronal death and Alzheimer’s disease. Curr. Mol. Med. 1, 733–737 (2001).[CrossRef][Medline]
- Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., and Buxbaum, J.D. Correlation between elevated levels of amyloid-beta peptide in the brain and cognitive decline. JAMA 283, 1571–1577 (2000).[Abstract/Free Full Text]
- McGowan, E., Eriksen, J., and Hutton, M. A decade of modeling Alzheimer’s disease in transgenic mice. Trends Genet. 22, 281–289 (2006).[CrossRef][Medline]
- Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., and Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat. Med. 9, 448–452 (2003).[CrossRef][Medline]
- Patton, R.L., Kalback, W.M., Esh, C.L. et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer’s disease patients: a biochemical analysis. Am. J. Pathol. 169, 1048–1063 (2006).[Abstract/Free Full Text]
- Gilman, S., Koller, M., Black, R.S. et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553–1562 (2005).[Abstract/Free Full Text]
- Zhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S.A., Liao, F.F., Xu, H., and Zhang, Y.W. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J. Biol. Chem. 282, 10873–10880 (2007).[Abstract/Free Full Text]
- Szczygielski, J., Mautes, A., Steudel, W.I., Falkai, P., Bayer, T.A., and Wirths, O. Traumatic brain injury: Cause or risk of Alzheimer’s disease? A review of experimental studies. J. Neural Transm. 112, 1547–1564 (2005).[CrossRef][Medline]
- Zetterberg, H., Hietala, M.A., Jonsson, M. et al. Neurochemical aftermath of amateur boxing. Arch. Neurol. 63, 1277–1280 (2006).[Abstract/Free Full Text]
- Robichaud, A.J. Approaches to palliative therapies for Alzheimer’s disease. Curr. Top. Med. Chem. 6, 553–568 (2006).[CrossRef][Medline]
- Karlawish, J.H. Donepezil delay to nursing home placement study is flawed. J. Am. Geriatr. Soc. 52, 845–846 (2004).[Medline]
- Caccamo, A., Oddo, S., Billings, L.M., Green, K.N., Martinez-Coria, H., Fisher, A., and Laferla, F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49, 671–682 (2006). The authors demonstrate that the M1 muscarinic agonist AF267B lowers Aß42, reduces tau hyperphosphorylation, and improves cognition in their triple transgenic model of AD, presumably through a novel indirect amyloid-altering pathway.[CrossRef][Medline]
- Fisher, A., Pittel, Z., Haring, R. et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: implications in future therapy. J. Mol. Neurosci. 20, 349–356 (2003).[CrossRef][Medline]
- Poorkaj, P., Bird, T.D., Wijsman, E. et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815–825 (1998).[CrossRef][Medline]
- Hutton, M., Lendon, C.L., Rizzu, P. et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702–705 (1998).[CrossRef][Medline]
- Baker, M., Litvan, I., Houlden, H. et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8, 711–715 (1999).[Abstract/Free Full Text]
- Houlden, H., Baker, M., Morris, H.R. et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56, 1702–1706 (2001).[Abstract/Free Full Text]
- Reed, L.A., Wszolek, Z.K., and Hutton, M. Phenotypic correlations in FTDP-17. Neurobiol. Aging 22, 89–107 (2001).[CrossRef][Medline]
- Dickey, C.A., Kamal, A., Lundgren, K. et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117, 648–658 (2007).[CrossRef][Medline]
- Pickhardt, M., Larbig, G., Khlistunova, I., Coksezen, A., Meyer, B., Mandelkow, E.M., Schmidt, B., and Mandelkow, E. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46, 10016–10023 (2007). The most extensive screening study published to date for compounds that inhibit tau aggregation.[CrossRef][Medline]
- Zhang, B., Maiti, A., Shively, S. et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. USA 102, 227–231 (2005).[Abstract/Free Full Text]
- Le Corre, S., Klafki, H.W., Plesnila, N. et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl. Acad. Sci. USA 103, 9673–9678 (2006). Interesting study that reports a non-selective kinase inhibitor that blocks the accumulation of aggregated hyperphosphorylated tau and the development of functional deficits in a widely used model of tauopathy.[Abstract/Free Full Text]
- Noble, W., Planel, E., Zehr, C. et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA 102, 6990–6995 (2005).[Abstract/Free Full Text]
- Ballatore, C., Lee, V.M., and Trojanowski, J.Q. Tau-mediated neuro-degeneration in Alzheimer’s disease and related disorders. Nat. Rev. Neurosci. 8, 663–672 (2007).[Medline]
- Mazanetz, M.P. and Fischer, P.M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug. Discov. 6, 464–479 (2007). Comprehensive review of the issues that surround kinase inhibition as a drug target for human tauopathy.[CrossRef][Medline]
- Farrer, L.A., Cupples, L.A., Haines, J.L. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349–1356 (1997).[Abstract/Free Full Text]
- Mahley, R.W., Weisgraber, K.H., and Huang, Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 103, 5644–5651 (2006).[Abstract/Free Full Text]
- Finehout, E.J., Franck, Z., Choe, L.H., Relkin, N., and Lee, K.H. Cerebrospinal fluid proteomic biomarkers for Alzheimer’s disease. Ann. Neurol. 61, 120–129 (2007).[CrossRef][Medline]
- Budge, M.M., De Jager, C., Hogervorst, E., and Smith, A.D. Total plasma homocysteine, age, systolic blood pressure, and cognitive performance in older people. J. Am. Geriatr. Soc. 50, 2014–2018 (2002).[CrossRef][Medline]
- Nurk, E., Tell, G.S., Vollset, S.E., Nygard, O., Refsum, H., and Ueland, P.M. Plasma total homocysteine and hospitalizations for cardiovascular disease: The Hordaland Homocysteine Study. Arch. Intern. Med. 162, 1374–1381 (2002).[Abstract/Free Full Text]
- Simonsen, A.H., McGuire, J., Hansson, O., Zetterberg, H., Podust, V.N., Davies, H.A., Waldemar, G., Minthon, L., and Blennow, K. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol. 64, 366–370 (2007).[Abstract/Free Full Text]
- Sontag, E., Nunbhakdi-Craig, V., Sontag, J.M., Diaz-Arrastia, R., Ogris, E., Dayal, S., Lentz, S.R., Arning, E., and Bottiglieri, T. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J. Neurosci. 27, 2751–2759 (2007).[Abstract/Free Full Text]
- Blain, J.F. and Poirier, J. Cholesterol homeostasis and the pathophysiology of Alzheimer’s disease. Expert Rev. Neurother. 4, 823–829 (2004).[Medline]
- Wolozin, B., Wang, S.W., Li, N.C., Lee, A., Lee, T.A., and Kazis, L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med, 5, 20 (2007).[CrossRef][Medline]
- Grimm, M.O., Grimm, H.S., Patzold, A.J. et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7, 1118–1123 (2005).[Medline]
- Riddell, D.R., Zhou, H., Comery, T.A. et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer’s disease. Mol. Cell. Neurosci. 34, 621–628 (2007).[CrossRef][Medline]
- Zelcer, N., Khanlou, N., Clare, R., Jiang, Q., Reed-Geaghan, E.G., Landreth, G.E., Vinters, H.V., and Tontonoz, P. Attenuation of neuroinflammation and Alzheimer’s disease pathology by liver x receptors. Proc. Natl. Acad. Sci. USA 104, 10601–10606 (2007).[Abstract/Free Full Text]
- Bu, G., Cam, J., and Zerbinatti, C. LRP in amyloid-beta production and metabolism. Ann. NY Acad. Sci. 1086, 35–53 (2006).[CrossRef][Medline]
- Kotti, T.J., Ramirez, D.M., Pfeiffer, B.E., Huber, K.M., and Russell, D.W. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. USA 103, 3869–3874 (2006).[Abstract/Free Full Text]
- Olkkonen, V.M., Johansson, M., Suchanek, M., Yan, D., Hynynen, R., Ehnholm, C., Jauhiainen, M., Thiele, C., and Lehto, M. The OSBP-related proteins (ORPs): global sterol sensors for co-ordination of cellular lipid metabolism, membrane trafficking and signalling processes? Biochem. Soc. Trans. 34, 389–391 (2006).[CrossRef][Medline]
- Rapoport, S.I., Hatanpaa, K., Brady, D.R., and Chandrasekaran, K. Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease. Neurodegeneration 5, 473–476 (1996).[CrossRef][Medline]
- Chen, X., Stern, D., and Yan, S.D. Mitochondrial dysfunction and Alzheimer’s disease. Curr. Alzheimer Res. 3, 515–520 (2006).[CrossRef][Medline]
- Scarmeas, N. and Stern, Y. Cognitive reserve and lifestyle. J. Clin. Exp. Neuropsychol. 25, 625–633 (2003).[Medline]
- Riley, K.P., Snowdon, D.A., Desrosiers, M.F., and Markesbery, W.R. Early life linguistic ability, late life cognitive function, and neuropathology: Findings from the Nun Study. Neurobiol. Aging 26, 341–347 (2005).[CrossRef][Medline]
- Adlard, P.A., Perreau, V.M., Pop, V., and Cotman, C.W. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer’s disease. J. Neurosci. 25, 4217–4221 (2005).[Abstract/Free Full Text]
- Lazarov, O., Robinson, J., Tang, Y.P. et al. Environmental enrichment reduces A-beta levels and amyloid deposition in transgenic mice. Cell 120, 701–713 (2005).[CrossRef][Medline]
- Billings, L.M., Green, K.N., McGaugh, J.L., and Laferla, F.M. Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J. Neurosci. 27, 751–761 (2007).[Abstract/Free Full Text]
- Velliquette, R.A., O’Connor, T., and Vassar, R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: Possible early events in Alzheimer’s disease pathogenesis. J. Neurosci. 25, 10874–10883 (2005).[Abstract/Free Full Text]
- Risner, M.E., Saunders, A.M., Altman, J.F., Ormandy, G.C., Craft, S., Foley, I.M., Zvartau-Hind, M.E., Hosford, D.A., and Roses, A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J. 6, 246–254 (2006).[Medline]
- Strum, J.C., Shehee, R., Virley, D. et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers. Dis. 11, 45–51 (2007).[Medline]
- McGeer, P.L., Rogers, J., and McGeer, E.G. Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. J. Alzheimers Dis. 9 , 271–276 (2006).[Medline]
- Chow, N., Bell, R.D., Deane, R., Streb, J.W., Chen, J., Brooks, A., Van Nostrand, W., Miano, J.M., and Zlokovic, B.V. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer’s phenotype. Proc. Natl. Acad. Sci. USA 104, 823–828 (2007).[Abstract/Free Full Text]
- Majercak, J., Ray, W.J., Espeseth, A. et al. LRRTM3 promotes processing of amyloid precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 103, 17967–17972 (2006). In an elegant example of an unbiased strategy for the identification of new therapeutic targets, the authors use siRNAs to screen 15,200 human genes for involvement in APP processing. LRRTM3, a novel regulator of APP processing, is identified in this work.[Abstract/Free Full Text]
- Park, J.H., Gimbel, D.A., GrandPre, T., Lee, J.K., Kim, J.E., Li, W., Lee, D.H., and Strittmatter, S.M. Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. J. Neurosci. 26, 1386–1395 (2006).[Abstract/Free Full Text]
- Seabrook, G.R., Smith, D.W., Bowery, B.J. et al. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 38, 349–359 (1999).[CrossRef][Medline]
- Torroja, L., Packard, M., Gorczyca, M., White, K., and Budnik, V. The Drosophila beta-amyloid precursor protein homolog promotes synapse differentiation at the neuromuscular junction. J. Neurosci. 19, 7793–7803 (1999).[Abstract/Free Full Text]
- Gralle, M. and Ferreira, S.T. Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts. Prog. Neurobiol. 82, 11–32 (2007).[CrossRef][Medline]
- Palop, J.J., Chin, J., and Mucke, L. A network dysfunction perspective on neurodegenerative diseases. Nature 443, 768–773 (2006).[CrossRef][Medline]
- Crowther, D.C., Page, R., Chandraratna, D., and Lomas, D.A. A Drosophila model of Alzheimer’s disease. Methods Enzymol. 412, 234–255 (2006).[Medline]
This article has been cited by other articles:
|
|
|
|
 
J. Kaye
Ginkgo biloba Prevention Trials: More Than an Ounce of Prevention Learned
Arch Neurol,
May 1, 2009;
66(5):
652 - 654.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Minati, T. Edginton, M. Grazia Bruzzone, and G. Giaccone
Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review
American Journal of Alzheimer's Disease and Other Dementias,
April 1, 2009;
24(2):
95 - 121.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. Torres-Aleman
Mouse Models of Alzheimer's Dementia: Current Concepts and New Trends
Endocrinology,
December 1, 2008;
149(12):
5952 - 5957.
[Abstract]
[Full Text]
[PDF]
|
|
|
Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.
TOP
Summary
Introduction